UNSPSC 51283517: Oxacillin sodium anhydrous

This classification denotes a penicillin antibiotic with the molecular formula C19H18N3O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TWD2995UP, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, sodium salt (1:1), (2s,5r,6r)-, but more generally known as oxacillin sodium anhydrous, which bears US NIH Compound Identifier 64714.

UNSPSC 51283517 Oxacillin sodium anhydrous is a Commodity code that, based on recent state and local solicitation activity, does not reflect the actual procurement patterns registered under it. The recent opportunities tagged to this code involve naloxone and drug deactivation systems, medical and first aid supplies for emergency response, therapeutic pharmacy initiatives, and multi-source generic pharmaceuticals and OTC products — none of which are oxacillin sodium anhydrous, a beta-lactam antibiotic. The code shows a substantial mismatch between its nominal scope and the diverse pharmaceutical, medical supply, and pharmacy program work being solicited across state and local jurisdictions, suggesting either categorization inconsistency in the source systems or that the code itself has been applied to a broader range of pharmaceutical procurement than its name indicates.

The issuing bodies purchasing under this code span state health agencies, county health departments, municipal fire departments, and cooperative purchasing alliances, including the Texas Health and Human Services Commission, Seminole County (Florida), the City of Tampa Fire Department, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Recent activity includes Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's sealed bid for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026, with SLBE set-aside and 5 percent discount available), MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026). Geographic activity centers on Florida, Minnesota, Texas, and Oregon, with the MMCAP cooperative vehicle serving multistate participation. The code shows little relevant recent activity tied to oxacillin sodium anhydrous specifically.